| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |